[go: up one dir, main page]

MX2020003719A - Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. - Google Patents

Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.

Info

Publication number
MX2020003719A
MX2020003719A MX2020003719A MX2020003719A MX2020003719A MX 2020003719 A MX2020003719 A MX 2020003719A MX 2020003719 A MX2020003719 A MX 2020003719A MX 2020003719 A MX2020003719 A MX 2020003719A MX 2020003719 A MX2020003719 A MX 2020003719A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
antibodies against
therapy involving
involving antibodies
Prior art date
Application number
MX2020003719A
Other languages
English (en)
Inventor
Ugur Sahin
Özlem Türeci
Original Assignee
Ganymed Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh filed Critical Ganymed Pharmaceuticals Gmbh
Publication of MX2020003719A publication Critical patent/MX2020003719A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5753—
    • G01N33/57585—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona generalmente una terapia para tratar y/o prevenir de manera efectiva enfermedades asociadas con células que expresan CLDN18.2, En particular enfermedades cancerosas tales como cáncer gastroesofágico. Se presentan datos que muestran que la administración del anticuerpo anti-CLDN18.2 a pacientes humanos con cáncer gastroesofágico es segura y bien tolerada hasta una dosis de al menos 1000 mg/m2. Adicionalmente, se presentan datos que muestran que el anticuerpo es completamente funcional en estos pacientes para ejecutar los efectos de células anti-tumor y se obtuvo evidencia para la actividad anti-tumoral.
MX2020003719A 2013-03-18 2015-09-18 Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. MX2020003719A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/000817 WO2014146672A1 (en) 2013-03-18 2013-03-18 Therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2020003719A true MX2020003719A (es) 2020-07-22

Family

ID=48182875

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013355A MX372883B (es) 2013-03-18 2014-03-17 Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
MX2020003719A MX2020003719A (es) 2013-03-18 2015-09-18 Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013355A MX372883B (es) 2013-03-18 2014-03-17 Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.

Country Status (18)

Country Link
US (3) US10137195B2 (es)
JP (5) JP6416197B2 (es)
KR (3) KR102490997B1 (es)
CN (1) CN105189554B (es)
AU (5) AU2014234684B2 (es)
BR (1) BR112015023910B1 (es)
CA (1) CA2899770C (es)
DK (1) DK2976360T3 (es)
ES (1) ES2765949T3 (es)
HU (1) HUE048541T2 (es)
IL (3) IL305017A (es)
MX (2) MX372883B (es)
MY (1) MY191040A (es)
PT (1) PT2976360T (es)
RU (1) RU2678700C2 (es)
SG (2) SG11201507764QA (es)
UA (1) UA119036C2 (es)
WO (2) WO2014146672A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165765A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
JP7587921B2 (ja) * 2016-07-08 2024-11-21 クレージュ メディカル カンパニー，リミテッド 抗クローディンタンパク質１８ａ２の抗体及びその応用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7398380B2 (ja) 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド 抗クローディン１８．２抗体及びその使用
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
US11912763B2 (en) 2018-06-17 2024-02-27 L & L Biopharma Co., Ltd. Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
TWI830761B (zh) * 2018-08-03 2024-02-01 德商安美基研究（慕尼黑）公司 針對cldn18.2和cd3之抗體構建體
EP3878863A4 (en) * 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
US20220033491A1 (en) * 2018-09-30 2022-02-03 Cafa Therapeutics Limited Combination therapy of cldn18 antibody and chemotherapy drugs
JP7458399B2 (ja) * 2018-12-07 2024-03-29 ゼットリップ ホールディング リミテッド 抗クローディン抗体及びそれらの使用
EP3904386A4 (en) * 2018-12-28 2022-09-07 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTIBODIES AND USE THEREOF
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN117659190A (zh) * 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
EP3971208A4 (en) 2019-05-16 2022-11-30 Qilu Pharmaceutical Co., Ltd. ANTIBODIES TO CLAUDIN 18A2 AND USE THEREOF
WO2020238730A1 (zh) * 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 新型cldn18.2结合分子
KR102758039B1 (ko) * 2019-05-30 2025-01-22 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체
MX2022000652A (es) * 2019-07-17 2022-06-02 Univ California Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MY207446A (en) * 2019-08-12 2025-02-27 Abl Bio Inc Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
CA3149406A1 (en) * 2019-08-20 2021-02-25 Xueming Qian Novel anti-cldn18.2 antibodies
WO2021047599A1 (en) * 2019-09-13 2021-03-18 Beijing Xuanyi Pharmasciences Co., Ltd. Humanized anti-claudin 18.2 (cldn18.2) antibodies
CN112707965A (zh) 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
JP7641967B2 (ja) * 2019-12-06 2025-03-07 ソティオ バイオテック エイ．エス． ヒト化ｃｌｄｎ１８．２抗体
MX2022014896A (es) * 2020-05-25 2023-01-04 Suzhou Transcenta Therapeutics Co Ltd Anticuerpos anti-cldn18.2 y usos para diagnostico de los mismos.
WO2021239026A1 (zh) * 2020-05-29 2021-12-02 杭州邦顺制药有限公司 针对Claudin18.2的抗体及其用途
EP4168454A4 (en) * 2020-06-23 2024-10-02 Antengene Biologics Limited ANTIBODIES AND METHODS FOR THE TREATMENT OF CLAUDIN-ASSOCIATED DISEASES
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技（成都）有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022100590A1 (zh) * 2020-11-10 2022-05-19 齐鲁制药有限公司 针对密蛋白18a2的adcc增强型人源化抗体及其应用
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
JP2024531944A (ja) 2021-08-09 2024-09-03 ハーバー バイオメッド（シャンハイ）カンパニー リミテッド Ｃｌｄｎ１８．２標的化抗体、二重特異性抗体、及びそれらの使用
JP2025513801A (ja) 2022-04-08 2025-04-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多部位受容体及びシグナル伝達複合体
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
CN119101162A (zh) * 2023-06-07 2024-12-10 江苏奥赛康生物医药有限公司 一种抗cldn18_2的抗体及体外诊断试剂盒
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
CN117567625B (zh) * 2023-11-21 2025-07-22 中国医学科学院医药生物技术研究所 一种抗Claudin18.2单克隆抗体及其应用
CN117701719B (zh) * 2024-02-04 2024-05-31 北京肿瘤医院(北京大学肿瘤医院) 肿瘤靶向cldn18.2治疗耐药标志物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
CN119143798B (zh) * 2024-08-01 2025-09-30 河北医科大学 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP1144629A3 (en) 1998-09-01 2001-11-28 Genentech, Inc. Further pro polypeptides and sequences thereof
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
IL142012A0 (en) 1998-09-16 2002-03-10 Zymogenetics Inc Stomach polypeptide zsig28
EP1119620A2 (en) 1998-10-06 2001-08-01 Curagen Corporation Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3951035B2 (ja) 1999-09-01 2007-08-01 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
CA2396719A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. 22 human secreted proteins
EP1259531A2 (en) 2000-01-31 2002-11-27 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2397407A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
JP2004519215A (ja) 2000-08-15 2004-07-02 イミュネックス・コーポレーション クローディンポリペプチド
US20030017468A1 (en) 2000-08-28 2003-01-23 Sei-Yu Chen Compositions and methods relating to lung specific genes
MXPA03002049A (es) 2000-09-08 2003-07-24 Schering Corp Genes de mamiferos: reactivos y metodos relacionados.
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP1929003A4 (en) 2005-08-31 2009-04-29 Cell Signaling Technology Inc REAGENTS FOR DETECTION OF PROTEIN PHOSPORYLATION IN CARCINOMA SIGNALING PATHWAYS
CA2623775A1 (en) 2005-09-19 2007-03-29 Veridex, Llc Methods and materials for identifying the origin of a carcinoma of unknown primary origin
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR101296264B1 (ko) * 2006-02-09 2013-08-14 암젠 리서치 (뮌헨) 게엠베하 전이성 유방암의 치료
WO2008013954A2 (en) 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
WO2008095152A2 (en) 2007-02-01 2008-08-07 Veridex, Llc Methods and materials for identifying the origin of a carcinoma of unknown primary origin
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
AU2025205333A1 (en) 2025-07-31
KR20230015514A (ko) 2023-01-31
US11395852B2 (en) 2022-07-26
CN105189554B (zh) 2021-10-08
JP2020143153A (ja) 2020-09-10
HK1219486A1 (en) 2017-04-07
US10137195B2 (en) 2018-11-27
JP7018361B2 (ja) 2022-02-10
IL240060B2 (en) 2023-05-01
BR112015023910B1 (pt) 2019-09-10
IL299004B2 (en) 2024-02-01
JP2024056803A (ja) 2024-04-23
AU2019201513B2 (en) 2020-08-13
ES2765949T8 (es) 2020-06-23
JP2018184403A (ja) 2018-11-22
DK2976360T3 (da) 2020-01-27
JP7633968B2 (ja) 2025-02-20
PT2976360T (pt) 2020-01-22
KR102490997B1 (ko) 2023-01-25
KR20240096827A (ko) 2024-06-26
SG10201707684WA (en) 2017-11-29
WO2014146672A1 (en) 2014-09-25
US20190076525A1 (en) 2019-03-14
AU2019201513A1 (en) 2019-03-28
AU2020210165B2 (en) 2022-07-14
JP2016517447A (ja) 2016-06-16
JP7166310B2 (ja) 2022-11-07
CA2899770C (en) 2025-05-27
US20160008465A1 (en) 2016-01-14
IL299004A (en) 2023-02-01
WO2014146778A1 (en) 2014-09-25
ES2765949T3 (es) 2020-06-11
IL299004B1 (en) 2023-10-01
JP6416197B2 (ja) 2018-10-31
KR20150130318A (ko) 2015-11-23
US20220184209A1 (en) 2022-06-16
RU2015144666A (ru) 2017-04-21
JP2022133424A (ja) 2022-09-13
SG11201507764QA (en) 2015-10-29
MX372883B (es) 2020-07-08
CA2899770A1 (en) 2014-09-25
AU2022246477B2 (en) 2025-04-17
NZ710648A (en) 2021-03-26
BR112015023910A2 (pt) 2017-03-21
MY191040A (en) 2022-05-30
RU2015144666A3 (es) 2018-03-26
AU2014234684B2 (en) 2018-12-06
IL240060B1 (en) 2023-01-01
MX2015013355A (es) 2016-06-24
JP7798932B2 (ja) 2026-01-14
CN105189554A (zh) 2015-12-23
UA119036C2 (uk) 2019-04-25
AU2014234684A1 (en) 2015-08-20
IL305017A (en) 2023-10-01
AU2022246477A1 (en) 2022-11-03
IL240060A0 (en) 2015-09-24
RU2019101923A (ru) 2019-02-22
AU2020210165A1 (en) 2020-08-13
RU2678700C2 (ru) 2019-01-31
HUE048541T2 (hu) 2020-07-28

Similar Documents

Publication Publication Date Title
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
CR20160186A (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
MX2020006650A (es) Esketamina para el tratamiento de la depresión.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2016015346A (es) Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX338047B (es) Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
NZ760040A (en) Methods of treating brain tumors using combination therapy
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.